Skip to Content
Merck
  • Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.

Probing binding requirements of type I and type II isoforms of inosine monophosphate dehydrogenase with adenine-modified nicotinamide adenine dinucleotide analogues.

Journal of medicinal chemistry (2007-10-26)
Liqiang Chen, Guangyao Gao, Krzysztof Felczak, Laurent Bonnac, Steven E Patterson, Daniel Wilson, Eric M Bennett, Hiremagalur N Jayaram, Lizbeth Hedstrom, Krzysztof W Pankiewicz
ABSTRACT

Novel tiazofurin adenine dinucleotide (TAD) analogues 25-33 containing a substituent at C2 of the adenine ring have been synthesized as inhibitors of the two isoforms of human IMP-dehydrogenase. The 2-ethyl TAD analogue 33 [Ki = 1 nM (type I), Ki = 14 nM (type II)] was found to be the most potent. It did not inhibit three other cellular dehydrogenases up to 50 microM. Mycophenolic adenine bis(phosphonate)s containing a 2-phenyl (37) or 2-ethyl group (38), were prepared as metabolically stable compounds, both nanomolar inhibitors. Compound 38 [Ki = 16 nM (type I), Ki = 38 nM (type II)] inhibited proliferation of leukemic K562 cells (IC50 = 1.1 microM) more potently than tiazofurin (IC50 = 12.4 microM) or mycophenolic acid (IC50 = 7.7 microM).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Mycophenolic acid, ≥98%
Sigma-Aldrich
Mycophenolic acid, powder, BioReagent, suitable for cell culture